Axonics Inc(NASDAQ:AXNX) stock Fundamental Analysis

Fundamental Rating

Overall AXNX gets a fundamental rating of 5 out of 10. We evaluated AXNX against 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for AXNX as it has an excellent financial health rating, but there are worries on the profitability. AXNX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

AXNX had negative earnings in the past year.

In the past year AXNX had a positive cash flow from operations.

In the past 5 years AXNX always reported negative net income.

In the past 5 years AXNX reported 4 times negative operating cash flow.

1.2 Ratios

AXNX has a Return On Assets of -0.73%. This is in the better half of the industry: AXNX outperforms 67.91% of its industry peers.

Looking at the Return On Equity, with a value of -0.85%, AXNX is in the better half of the industry, outperforming 68.98% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-0.73%
ROE	-0.85%
ROIC	N/A

ROA(3y)-8.17%

ROA(5y)-15.38%

ROE(3y)-9.34%

ROE(5y)-18.16%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AXNX's Gross Margin of 76.59% is amongst the best of the industry. AXNX outperforms 89.30% of its industry peers.

In the last couple of years the Gross Margin of AXNX has grown nicely.

AXNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	76.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.58%

GM growth 5Y5.57%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AXNX does not have a ROIC to compare to the WACC, probably because it is not profitable.

AXNX has more shares outstanding than it did 1 year ago.

AXNX has more shares outstanding than it did 5 years ago.

AXNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 20.38 indicates that AXNX is not in any danger for bankruptcy at the moment.

AXNX's Altman-Z score of 20.38 is amongst the best of the industry. AXNX outperforms 93.58% of its industry peers.

AXNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	20.38

ROIC/WACCN/A

WACC9.07%

2.3 Liquidity

A Current Ratio of 8.16 indicates that AXNX has no problem at all paying its short term obligations.

AXNX's Current ratio of 8.16 is amongst the best of the industry. AXNX outperforms 87.70% of its industry peers.

A Quick Ratio of 6.40 indicates that AXNX has no problem at all paying its short term obligations.

AXNX has a Quick ratio of 6.40. This is amongst the best in the industry. AXNX outperforms 85.03% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.16
Quick Ratio	6.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for AXNX have decreased strongly by -116.67% in the last year.

Looking at the last year, AXNX shows a very strong growth in Revenue. The Revenue has grown by 26.08%.

The Revenue has been growing by 249.76% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-116.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-100%

Revenue 1Y (TTM)26.08%

Revenue growth 3Y48.67%

Revenue growth 5Y249.76%

Sales Q2Q%24.8%

3.2 Future

Based on estimates for the next years, AXNX will show a very strong growth in Earnings Per Share. The EPS will grow by 69.51% on average per year.

Based on estimates for the next years, AXNX will show a quite strong growth in Revenue. The Revenue will grow by 19.14% on average per year.

EPS Next Y56.54%

EPS Next 2Y120.11%

EPS Next 3Y100.31%

EPS Next 5Y69.51%

Revenue Next Year23.72%

Revenue Next 2Y21.8%

Revenue Next 3Y20.53%

Revenue Next 5Y19.14%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AXNX. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 81.39, the valuation of AXNX can be described as expensive.

Based on the Price/Forward Earnings ratio, AXNX is valued a bit cheaper than the industry average as 65.78% of the companies are valued more expensively.

Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, AXNX is valued quite expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	81.39

4.2 Price Multiples

62.57% of the companies in the same industry are more expensive than AXNX, based on the Enterprise Value to EBITDA ratio.

66.84% of the companies in the same industry are more expensive than AXNX, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	675.06
EV/EBITDA	603.04

4.3 Compensation for Growth

AXNX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

A more expensive valuation may be justified as AXNX's earnings are expected to grow with 100.31% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y120.11%

EPS Next 3Y100.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AXNX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Axonics Inc

NASDAQ:AXNX (11/14/2024, 8:04:51 PM)

After market: 70.98 0 (0%)

70.98

+0.53 (+0.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-07 2024-11-07/amc

Earnings (Next)N/A N/A

Inst Owners85.44%

Inst Owner Change-100%

Ins Owners5.35%

Ins Owner Change-24.27%

Market Cap3.63B

Analysts68.42

Price Target73.33 (3.31%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-50.5%

Min EPS beat(2)-100%

Max EPS beat(2)-1.01%

EPS beat(4)1

Avg EPS beat(4)-49.29%

Min EPS beat(4)-215.13%

Max EPS beat(4)118.99%

EPS beat(8)5

Avg EPS beat(8)52.84%

EPS beat(12)9

Avg EPS beat(12)41.69%

EPS beat(16)11

Avg EPS beat(16)30.84%

Revenue beat(2)2

Avg Revenue beat(2)0.21%

Min Revenue beat(2)0.05%

Max Revenue beat(2)0.37%

Revenue beat(4)3

Avg Revenue beat(4)0.07%

Min Revenue beat(4)-0.36%

Max Revenue beat(4)0.37%

Revenue beat(8)7

Avg Revenue beat(8)1.85%

Revenue beat(12)11

Avg Revenue beat(12)3.83%

Revenue beat(16)13

Avg Revenue beat(16)4.5%

PT rev (1m)0.23%

PT rev (3m)0.23%

EPS NQ rev (1m)21.53%

EPS NQ rev (3m)21.53%

EPS NY rev (1m)-2.83%

EPS NY rev (3m)5.04%

Revenue NQ rev (1m)0.94%

Revenue NQ rev (3m)0.94%

Revenue NY rev (1m)-0.11%

Revenue NY rev (3m)0.23%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	81.39
P/S	8.4
P/FCF	675.06
P/OCF	253.73
P/B	5.46
P/tB	7.53
EV/EBITDA	603.04

EPS(TTM)-0.01

EYN/A

EPS(NY)0.87

Fwd EY1.23%

FCF(TTM)0.11

FCFY0.15%

OCF(TTM)0.28

OCFY0.39%

SpS8.45

BVpS13

TBVpS9.42

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.73%
ROE	-0.85%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	76.59%
FCFM	1.24%

ROA(3y)-8.17%

ROA(5y)-15.38%

ROE(3y)-9.34%

ROE(5y)-18.16%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.58%

GM growth 5Y5.57%

F-Score6

Asset Turnover0.56

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	71.48%
Cap/Sales	2.07%
Interest Coverage	N/A
Cash Conversion	271.41%
Profit Quality	N/A
Current Ratio	8.16
Quick Ratio	6.4
Altman-Z	20.38

F-Score6

WACC9.07%

ROIC/WACCN/A

Cap/Depr(3y)24.04%

Cap/Depr(5y)70.74%

Cap/Sales(3y)1.01%

Cap/Sales(5y)3.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-116.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-100%

EPS Next Y56.54%

EPS Next 2Y120.11%

EPS Next 3Y100.31%

EPS Next 5Y69.51%

Revenue 1Y (TTM)26.08%

Revenue growth 3Y48.67%

Revenue growth 5Y249.76%

Sales Q2Q%24.8%

Revenue Next Year23.72%

Revenue Next 2Y21.8%

Revenue Next 3Y20.53%

Revenue Next 5Y19.14%

EBIT growth 1Y33.24%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year377.96%

EBIT Next 3Y82.88%

EBIT Next 5Y66.14%

FCF growth 1Y133.78%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y210.5%

OCF growth 3YN/A

OCF growth 5YN/A

Axonics Inc (AXNX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens